All hands-on deck to fight the ‘zombie’ rabies virus
We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
Search
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
garbage game
Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
10 things you should know about rabies
10 things you should know about rabies
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Pride Month and our culture of respect
Watch our colleagues from the LGBTQIA+ community and allies share their views.
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Living with type 2 diabetes
People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Distributing medicine globally with pharmaceutical logistics
From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Bernard Mental Health Impact
Harold and Friends learn about how living with multiple health conditions can impact mental health
preventive care cat veterinarian
What can we all, cat owners or veterinarians, do to promote cat health? Click to find out!
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Fornovo
With its production facilities, Fornovo San Giovanni constitutes an important site for the production of core active pharmaceutical ingredients for both Human Pharma and Animal Health.